EUCTR2011-001312-59-GB进行中（未招募）不适用
A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (treprostinil sodium), in Pulmonary Arterial Hypertension Patients - Efficacy of capsaicin 8% patches in Pulmonary Arterial Hypertension
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients 18 years or older with symptomatic PAH. 2.Willing to provide written informed consent to participate in the study. 3.With documented diagnosis of PAH, either idiopathic, familial or associated with connective tissue disease, congenital heart disease or the use of anorexogenic drugs. 4.Documented haemodynamic diagnosis of PAH by right heart catheterization – performed at any time prior to screening, showing: mean pulmonary arterial pressure >25 mm Hg, pulmonary capillary wedge pressure =/< 15 mmHg and pulmonary vascular resistance >240 dynes/sec/cm5. 5.Receiving stable doses of Remodulin® SC, continuously infused at a dose of at least 2.5 ng/kg/min for at least 8 weeks prior to enrolment. Additional medications that are approved for treatment of PAH (either bosentan or sildenafil) and other supplementary treatments such as oral anticoagulants, diuretics, digitalis, calcium channel blockers or oxygen supplementation are permitted. 6.History of pain at the site of Remodulin® SC infusion for at least 8 weeks prior to enrolment and as assessed on the 11 point pain intensity numerical pain rating scale (NPRS) from 0 to 10, where 0 represents No pain and 10 represents Maximum pain imaginable”. Patients with a history of pain intensity equal or greater than 3 NPRS points (as determined by the NPRS trial diary completed during the screening period) are eligible to participate. [The use of systemic analgesics to relieve pain at the site of Remodulin® SC infusion, including salicylates, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, as well as topical analgesic-containing gels or creams (such as capsaicin 0.025% and 0.075% cream) and local anesthetics such as lidocaine are also permitted providing they remain unchanged for the entire duration of the study (i.e. from screening to the end of study follow up visit).] 7.Modified New York Heart Association (NYHA) (WHO) classification II-IV that has been stable for at least 8 weeks prior to enrolment. 8.A female subject is eligible to participate if she is of: •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol <40 pg/ml (<140 pmol/L) is confirmatory]. •Child-bearing potential and agrees to use one of the following contraception methods: oAbstinence oContraceptive Methods with a Failure Rate of < 1%: - Oral contraceptive, either combined or progestogen alone; - Injectable progestogen; - Implants of levonorgestrel; - Estrogenic vaginal ring; - Percutaneous contraceptive patches; - - Intrauterine device (IUD) or intrauterine system (IUS) that meets the <1% failure rate as stated in the product label; - Male partner(s) sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study; - Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps) plus vaginal spermicidal agent (foam/gel/film/cream/suppository).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patient’s participating in another clinical trial or who have done so within 30 days before screening. 2.Patients with PAH in NYHA/WHO functional class I at screening. 3.Known to be positive for human immunodeficiency virus (HIV). 4.Patients with any additional medical condition or illness that, in the opinion of the Investigator would interfere with study compliance and/or impair the patient's ability to participate or complete the study. Concurrent diseases or conditions that may interfere with study participation or safety include bleeding disorders, arrhythmias, organ transplant, organ failure, current neoplasm, poorly controlled diabetes mellitus, poorly controlled hypertension, clinically significant haematological or biochemical abnormality, and serious neurological disorders. 5.Patients with a history of substance abuse (e.g. alcohol or drug abuse) within the previous 6 months before enrolment. 6.Patients with a history of severe allergies or multiple drug allergies and/or reported hypersensitivity to capsaicin. 7.Patients with no history of pain at the site of Remodulin® SC infusion or average pain intensity at screening less than 3 points on the numerical pain rating scale (NPRS). 8.Life expectancy less than 12 months. 9.Unable to provide informed consent. 10.Female patients who are lactating or pregnant (positive pre-randomisation serum pregnancy test) or plan to become pregnant during the study.
研究者
相似试验
尚未招募
1 期
A randomized, double-blind, cross-over clinical trial of Sinisan in improving depression state of breast cancer patients with mild to moderate depressiomild to moderate depression of Breast cancer patientsITMCTR2200006710Zhiyu Wang
已完成
不适用
Randomized, double blind, crossover clinical study to evaluate the sedative effect after the treatment of 1 mg dose of ketotifen, or 10 or 20 mg dose of cetirizine using saccadic eye movement analysis in healthy male volunteersJPRN-UMIN000004527Department of Clinical Pharmacy, School of Pharmacy, Showa University6
已完成
3 期
Clinical trial on paraxanthine (PX) in comparison to that of caffeine (CF) in otherwise healthy volunteersCTRI/2022/03/041219Ingenious Ingredients24
招募中
1 期
A randomized, controlled, double-blind clinical study of Jiawei Qilang Decoction in the treatment of drug dependent constipatiodrug dependent constipationITMCTR2000003862Shanghai Municipal Hospital of Traditional Chinese Medicine
进行中（未招募）
不适用
A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic doses of inhaled QAB149 and salmeterolCOPD (chronic Obstructive Pulmonary Disease)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2007-001051-19-BEovartis Pharma Services AG24